Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
Earnings Data
Report Date
Aug 13, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.33Last Year’s EPS
-0.51Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 41.25%
|Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and positive reception from the medical community, but financial constraints and increased expenses remain challenges. The company's strategic focus on securing partnerships and financing is crucial for advancing their objectives.Company Guidance
During the Imunon first quarter 2025 financial results call, the company provided significant guidance on its Phase III OVATION 3 trial for IMNN-001, aimed at treating advanced ovarian cancer. The study, which has initiated its first clinical site, will include 500 patients in an all-comers population, with a focus on a 250-patient subgroup identified by a biomarker for homologous recombination deficiency (HRD). Primary and secondary endpoints include overall survival (OS), surgical response, and time to second-line treatment, with exploratory endpoints assessing quality of life to aid in future payer discussions. The trial is expected to cost 40% less by initially focusing on the HRD subgroup and could yield results two years earlier. Imunon also highlighted its financial status, with $2.9 million in cash as of March 31, 2025, and ongoing efforts to secure financing and partnerships to support its clinical milestones. The company is actively pursuing corporate partnerships, particularly in oncology and vaccine development, to cover the OVATION 3 trial costs, while emphasizing the potential of its PlaCCine vaccine technology.Initiation of Phase III OVATION 3 Trial
Imunon initiated the first clinical site for their Phase III pivotal study of Imunon-001 for ovarian cancer. The trial is recognized by the medical community and has received acceptance for presentations at major conferences.
Positive Reception from Medical Community
The OVATION 3 trial has been met with enthusiasm from leading hospitals and international investigators, many of whom participated in earlier phases of the study.
Financial Management and Strategy
Imunon is focused on securing value-added financing and partnerships to support their clinical timelines and strategic objectives, emphasizing cost-effective strategies and partnerships.
Oral Presentation at ASCO Annual Meeting
Imunon's OVATION 2 trial results were accepted for an oral presentation at the ASCO Annual Meeting, highlighting the significance of their research in the medical community.
IMNN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMNN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $0.80 | $0.82 | +2.50% |
Feb 27, 2025 | $0.80 | $0.81 | +1.25% |
Nov 07, 2024 | $0.94 | $0.82 | -12.77% |
Aug 14, 2024 | $1.08 | $0.96 | -11.11% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Imunon (IMNN) report earnings?
Imunon (IMNN) is schdueled to report earning on Aug 13, 2025, TBA Not Confirmed.
What is Imunon (IMNN) earnings time?
Imunon (IMNN) earnings time is at Aug 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMNN EPS forecast?
IMNN EPS forecast for the fiscal quarter 2025 (Q2) is -0.33.